Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Funding

    EU4Health- Programme

    Funding programme, Funded by: European Union, Submission deadline: 31/12/2027
    https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
  • Press release - 04/03/2021

    Induced pluripotent stem cells reveal causes of disease

    Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/induced-pluripotent-stem-cells-reveal-causes-disease
  • Development of the genomDE genome database - 04/12/2020 national-cancer-institute-to8o0bqOA6Q-unsplash.jpg

    Whole genome sequencing for diagnosing rare diseases

    Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…

    https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
  • Press release - 04/02/2020 Labor_CeGaT_GmbH.jpg

    CeGaT Brings New Dimension to Exome Diagnostics

    CeGaT aims to solve all genetically-caused cases of disease to help physicians state a diagnosis. To pursue this goal, CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool: CeGaT Exome Xtra is the most powerful genetic diagnostic option for patients with complex, unspecific, and rare diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-ermoeglicht-neue-dimension-der-exom-diagnostik
  • Expert interview on NTDs – part 3 - 24/09/2019 Curevac_Franz-Werner_Haas_.png

    Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies

    Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
  • Expert interview on NTDs – part 2 - 29/05/2019 The photo shows good footwear and people sitting in front of the shoes. Only the legs and feet can be seen. They are oedematous. The ground on which the shoes are standing is of a sandy texture and partially covered with straw.

    Neglected tropical diseases - Gisela Schneider: the burden of disease

    "Leaving no one behind". The motto of the 2030 Agenda with its 17 Sustainable Development Goals (SDGs) which was signed by the United Nations (UN) in 2015 makes clear that combatting poverty and its consequences is an essential part of sustainable development. The fight against neglected tropical diseases (NTDs) is defined as a major aim of the Agenda’s sustainable development goals. The World Health Organisation (WHO) regards twenty…

    https://www.gesundheitsindustrie-bw.de/en/article/news/neglected-tropical-diseases-gisela-schneider-the-burden-of-disease
  • Expert interview - 13/05/2019 Telemedizin: Vitor Vieira (Inova DE) mit einem selbst entwickelten Wearable, einem T-Shirt zur verbesserten Interaktion zwischen Patienten und Kardiologen für fernkontrolliertes Monitoring

    Innovation management in the life sciences – Inova DE provides insights

    Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
  • Expert interview on NTDs – part 1 - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Article - 30/10/2018 Zu sehen ist eine Karte der trinationalen Region am Oberrhein, auf der die verschiedenen Universitäten und Forschungseinrichtungen markiert sind.

    Eucor – bringing the European Campus to life

    Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Expert interview - 26/06/2018 Photo of Dr. med. Dr. rer. nat. Saskia Biskup.

    Genome analyses: "Germany lags behind dramatically"

    Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
  • Big Data - 26/03/2018 Schematic showing how data of a patient from different sources such as imaging and molecular diagnostics along with expert comments are combined and used for making a decision.

    Eliciting reliable information from big data with classifiers and multimodal data fusion

    Prof. Hans A. Kestler knows a great deal about large amounts of data. He heads up the Institute of Medical Systems Biology at the University of Ulm and is constantly inundated with cooperation enquiries from clinicians. On behalf of BIOPRO, Walter Pytlik asked him whether the conditions for using big data more in biomedical research are already largely present.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eliciting-reliable-information-from-big-data-with-classifiers-and-multimodal-data-fusion
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Company profile - 04/09/2017 Colour photo of Prof. Dr. François Paquet-Durand (left) and Barbara Brunnhuber (right).

    Mireca: a new drug for stopping the progression of eye diseases

    A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mireca-a-new-drug-for-stopping-the-progression-of-eye-diseases
  • Article - 24/05/2017 A small moss plant on a finger.

    Ralf Reski: from moss to humans

    Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
  • Article - 08/08/2016 Schematic cut through an eye into which the gene therapy is injected.

    First achromatopsia gene therapy clinical trial in Germany is going well

    Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…

    https://www.gesundheitsindustrie-bw.de/en/article/news/first-achromatopsia-gene-therapy-clinical-trial-in-germany-is-going-well
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 18/08/2014 Photo of a hand holding a syringe containing a dark fluid towards a naked upper arm.

    The use of human genes as medical products

    In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products
  • Article - 04/08/2014 Photo showing an electron microscope image of adeno-associated viruses (AAV).

    Europe’s first gene therapy

    Scientists from the National Center for Tumour Diseases (NCT) have shown that adeno-associated viruses (AAV) do not pose a cancer risk. This conclusion is based on the analysis of several million patient cells treated with AAV and the finding that the viruses do not integrate into the patient genome. AAV is the first-ever gene therapy for clinical use in the Western world. AAV vectors could also potentially be used as prototypes for the treatment…

    https://www.gesundheitsindustrie-bw.de/en/article/news/europe-s-first-gene-therapy
  • Article - 18/03/2013 Electron microscope image of small S100A6 aggregates that form larger fibrils.

    Protein depositions in the brain promote the development of amyotrophic lateral sclerosis (ALS)

    Being aware of ones own physical degradation as intellect and cognition remain completely intact this is what the disease amyotrophic lateral sclerosis ALS also known as Lou Gehrigs disease means to sufferers. The disease is currently not curable as far too little is known as yet about its causes. However basic research is making progress and providing increasing insights into the causes of ALS. Dr. Günter Fritz and his colleagues from the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/protein-depositions-in-the-brain-promote-the-development-of-amyotrophic-lateral-sclerosis-als
  • Article - 18/12/2012 18996_de.jpg

    Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie?

    Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
  • Article - 17/12/2012 18981_de.jpg

    Rare diseases – the long road to correct diagnosis and treatment

    Rare diseases are conditions that are too often neglected by research, industry and medicine. Here we use Wilson’s disease as an example to illustrate the particular problems associated with research into and treatment of rare diseases and to provide information on measures that can be taken to improve the situation of people with rare diseases. These measures include central treatment and care institutions and programmes like the Wilson’s…

    https://www.gesundheitsindustrie-bw.de/en/article/news/rare-diseases-the-long-road-to-correct-diagnosis-and-treatment
  • Press release - 13/11/2012 18685_de.jpg

    immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment

    immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
  • Article - 26/03/2012 16790_de.jpg

    More public attention for exotic diseases - Part 1

    An international conference on rare diseases was held in Freiburg Germany in February 2012 where BIOPRO talked with Prof. Dr. Bodo Grimbacher director of the Centre of Chronic Immunodeficiency CCI in Freiburg and Prof. Dr. Maximilian Muenke paediatrician and human geneticist from the National Human Genome Research Institute NHGRI in the USA. Between them the two experts have a great deal of experience in rare diseases amongst other areas. Read in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-public-attention-for-exotic-diseases-part-1
  • Article - 26/03/2012 16790_de.jpg

    More public attention for exotic diseases - Part 2

    An international conference on rare diseases was held in Freiburg Germany in February 2012 where BIOPRO talked with Prof. Dr. Bodo Grimbacher director of the Centre of Chronic Immunodeficiency CCI in Freiburg and Prof. Dr. Maximilian Muenke paediatrician and human geneticist from the National Human Genome Research Institute NHGRI in the USA. Between them the two experts have a great deal of experience in rare diseases amongst other areas. Read in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-public-attention-for-exotic-diseases-part-2

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search